Olema Oncology
Krishna Singh has a strong background in clinical quality and regulatory affairs, with experience ranging from Clinical Research Coordinator to Director-level positions in companies like Olema Oncology, Constellation Pharmaceuticals, and EMD Serono, Inc. Krishna has expertise in developing and maintaining QA systems, conducting audits, providing GCP training, and ensuring compliance with regulations. Singh's work history demonstrates a progression of responsibilities and leadership roles within the pharmaceutical and healthcare industry.
Krishna Singh completed an Associate's degree in Science in 2001 at Thakur College of Science & Commerce and in 2002 from Keystone College in Biological Science. Following this, from 2003 to 2005, Singh pursued a Bachelor's Degree in Health Administration at East Stroudsburg University of Pennsylvania. Later, from 2011 to 2015, Singh graduated with a Master of Business Administration (M.B.A.) in Health/Health Care Administration/Management from Ashford University. Additionally, Krishna Singh has obtained certifications in GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) from CITI Program in 2023 and in Trial Master File Professionals Program: TMF Discovery from IAOCR in 2021.
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.